Last updated: July 16, 2026
Bausch Health Ireland Limited v. Mylan Laboratories Ltd. (D.N.J.) 1:21-cv-00611: Litigation Summary, Claims, and Generic-Entry Risk
Bausch Health Ireland Limited sued Mylan Laboratories Ltd. in the District of New Jersey under the Hatch-Waxman framework (Paragraph IV context) in case 1:21-cv-00611. The record in this chat does not provide the operative complaint, asserted patent numbers, Orange Book-listed drug, claim charts, or the court’s substantive rulings. Without those case-specific inputs, a complete and accurate litigation summary and IP-expiration analysis cannot be produced.
What patents were asserted in Bausch Health Ireland Limited v. Mylan Laboratories Ltd. 1:21-cv-00611?
Answer: The asserted patent(s), application numbers, and claim scope are not provided in the source material available in this chat.
Which patent types were targeted (composition, method-of-use, formulation, or manufacturing)?
Answer: Not determinable from the provided case identifier alone.
Who are the named patent assignees and inventors?
Answer: Not determinable from the provided case identifier alone.
What drug and Orange Book listing drove Bausch Health Ireland Limited’s claims in 1:21-cv-00611?
Answer: The FDA product (brand/generic, strength, dosage form) and the specific Orange Book listing(s) are not provided in the source material available in this chat.
Was the case tied to an ANDA, Section 505(b)(2), or other FDA pathway?
Answer: Not determinable from the provided case identifier alone.
What Paragraph IV certifications were pled (and against which patents)?
Answer: Not determinable from the provided case identifier alone.
What was the litigation posture in 1:21-cv-00611 (filed claims, motions, and rulings)?
Answer: The procedural history, including any motion-to-dismiss, summary judgment, claim construction (Markman), injunction rulings, and final disposition, is not provided in the source material available in this chat.
Were there Markman proceedings and did the court construe key claim terms?
Answer: Not determinable from the provided case identifier alone.
Did the court enter an injunction or deny one?
Answer: Not determinable from the provided case identifier alone.
How strong were the asserted patents in Bausch Health Ireland Limited v. Mylan Laboratories Ltd. 1:21-cv-00611?
Answer: Patent strength cannot be evaluated without the asserted claims and the court’s merits rulings (or the infringement/noninfringement positions and invalidity arguments).
What invalidity theories were raised (novelty, obviousness, §112, indefiniteness, anticipation)?
Answer: Not determinable from the provided case identifier alone.
What infringement theories were pled (literal, doctrine of equivalents, product-by-process)?
Answer: Not determinable from the provided case identifier alone.
When did exclusivity or patent expiration occur for the relevant Bausch Health product in 1:21-cv-00611?
Answer: No patent expiration, pediatric exclusivity, or marketing exclusivity dates are provided in the source material available in this chat.
When does the Orange Book patent list expire for the accused product?
Answer: Not determinable from the provided case identifier alone.
Were there regulatory exclusivity blockers (180-day exclusivity, market exclusivity, pediatric six-month extension)?
Answer: Not determinable from the provided case identifier alone.
Did Mylan Laboratories challenge Bausch Health’s patents via a Paragraph IV or other FDA certification, and what was the outcome?
Answer: FDA certification details and the outcome (including any settlement-triggered dates) are not provided in the source material available in this chat.
Was there a settlement agreement affecting launch timing?
Answer: Not determinable from the provided case identifier alone.
Did Mylan obtain approval or delistings that shifted the litigation economics?
Answer: Not determinable from the provided case identifier alone.
What generic entry risks exist from 1:21-cv-00611 for Mylan’s ANDA product?
Answer: Launch-risk assessment requires the asserted patent list, any court validity findings, and the status of the FDA application. None are available in the source material provided in this chat.
What barriers remained after any rulings (design-around, noninfringement, induced infringement)?
Answer: Not determinable from the provided case identifier alone.
What is the likely design-around space if formulation or method claims were asserted?
Answer: Not determinable from the provided case identifier alone.
How does this litigation compare with other Bausch Health vs. generic challenges in the same court?
Answer: Comparative analysis requires access to those other cases’ asserted patents, timelines, and outcomes. No additional cases are provided.
Are there repeated patent families or common claim elements across Bausch Health generics litigation?
Answer: Not determinable from the provided case identifier alone.
What is the current status of case 1:21-cv-00611 (dismissed, stayed, settled, or decided)?
Answer: The disposition is not provided in the source material available in this chat.
Was the case stayed pending FDA or related proceedings?
Answer: Not determinable from the provided case identifier alone.
What deadlines (trial, expert reports, discovery, dispositive motions) were set or missed?
Answer: Not determinable from the provided case identifier alone.
Key Takeaways
No litigation summary or IP-risk analysis can be produced from case 1:21-cv-00611 with the information available in this chat. A complete, accurate treatment requires the operative complaint and/or the court docket contents (asserted patents, claims, procedural rulings, and disposition), which are not present here.
FAQs
-
What patents did Bausch Health Ireland Limited assert against Mylan Laboratories in 1:21-cv-00611?
Not available in the provided source material.
-
Which FDA ANDA listing and Orange Book patents were implicated in this case?
Not available in the provided source material.
-
Did the court decide claim construction or grant summary judgment in 1:21-cv-00611?
Not available in the provided source material.
-
Was there a settlement that set a launch date for Mylan?
Not available in the provided source material.
-
Is Mylan’s generic product currently on the market or blocked by injunction/continuing litigation?
Not available in the provided source material.
References
None.
